Home / Industry News / 2010 / Novartis Should Pay $285 Million in Gender Lawsuit, Bias Lawyer Says

Novartis Should Pay $285 Million in Gender Lawsuit, Bias Lawyer Says

Source: PharmaManufacturing.com

May 19, 2010

Bloomberg.com

Print Email

Show More Content

More News:

Narcan-maker Opiant abandons bulimia drug

02/22/2019

Opiant Pharmaceuticals, a specialty pharmaceutical company developing medicines for addictions and drug overdose, has halted its trial for a nasal spray designed to treat bulimia nervosa.
Merck to buy Seattle-based biotech

02/21/2019

Merck has agreed to buy Seattle-based biotechnology company, Immune Design, with the goal of improving vaccine development.
Teva reaches global settlement for ‘pay-for-delay’ deals

02/20/2019

The Federal Trade Commission has been cracking down on deals struck by brand-name drugmakers who pay off generics companies for postponing the release of lower-cost alternatives onto the market.
After two deaths, FDA hits the brakes on leukemia treatment study

02/20/2019

The FDA has placed a partial hold on a phase 1 study into the study of a treatment for acute myeloid leukemia (AML).
Norvartis invests $115M more in biotech AveXis to double manufacturing

02/19/2019

The expansion is expected to add 200 jobs in North Carolina, helping the drugmaker manufacture meds for rare genetic diseases
US Supreme Court clears way for Indivior opioid generic

02/19/2019

The court's decision to reject Indivior's attempt to block copycats of its opioid addiction med is a win for generic drug maker Dr. Reddy's Laboratories
Biotech CEO takes aim at Pentagon for not funding PTSD drug

02/19/2019

The head of a small biotech firm had sharp words for the Pentagon over its lack of financial support for research into an experimental PTSD drug.
Merck, Pfizer post positive results for kidney cancer combo

02/19/2019

A combination of treatments from Merck and Pfizer has shown to extend the life of patients with advanced kidney cancer.
FDA announces new regulatory pathway for generics

02/18/2019

The U.S. FDA has announced new, efficient guidelines for the use of a novel pathway that provides incentives for developing generic versions of drugs that currently face little or no competition.
Bayer reclaims cancer drugs in Lilly-Loxo buyout

02/18/2019

Bayer has exercised its option, under a change-in-control clause in the collaboration agreement with Loxo Oncology, to obtain the exclusive licensing rights for the global development and commercialization of two cancer drugs.

Pharma Manufacturing

Join the discussion

Comments

After two deaths, FDA hits the brakes on leukemia treatment study

The FDA has placed a partial hold on a phase 1 study into the study of a…

India's Glenmark to launch US spin-off

Generic drugmaker Glenmark Pharmaceuticals plans to spin off its…

Biotech CEO takes aim at Pentagon for not funding PTSD drug

The head of a small biotech firm had sharp words for the Pentagon over its…

External Partnerships, Redefined

Why building the right manufacturing partnerships is fundamental to…

Norvartis invests $115M more in biotech AveXis to double manufacturing

The expansion is expected to add 200 jobs in North Carolina, helping the…

FDA issues six observations for Lupin plant

The U.S. FDA has issued six observations after the inspection of Lupin's…

FDA issues first warning letter under DSCA for opioid distribution

McKesson Corp is back in the spotlight for opioid-related violations —…

FDA warns of blood pressure med shortage

FDA Commissioner Scott Gottlieb and CDER Director Janet Woodcock released…

Former pharma exec accused of giving a lap dance as part of an opioid kickback scheme

A former sales executive from Insys Therapeutics reportedly once gave a…

Vertex fires COO for "personal behavior"

Vertex fired its chief operating officer/interim chief financial officer…

Puerto Rico Pharma: Battered but Unbroken

One year after Hurricane Maria, Puerto Rico's pharma industry is standing…

Top Pharma Manufacturing Predictions for 2019

From new tech to innovative business models and shifting regulations,…

Top 5 Drugs With the Biggest Growth Potential in 2019

In the coming year, several drugs that treat a range of diseases will far…

Boehringer cuts nearly 300 jobs in France

The company's French workforce will see 327 jobs cut but will also see 32…

Roche R&D exec leaves pharma for biotech, joins Voyager Therapeutics

Voyager Therapeutics appoints Omar Khwaja as its chief medical officer,…

Weighing and Dispensing: Do it Right

The weighroom is the entry point to manufacturing and a transition point…

CAPA and Root Cause Analysis

Recent FDA Warning Letters have cited insufficient corrective and…

Annual Product Reviews: How to Conduct an Effective Annual Product Quality Review

More than just a regulatory requirement, an APR helps the manufacturer to…

USP Updates <61> and <62> for Microbial Testing of Non-Steriles

Significant changes include more clarity on enumberation and specified…

Serialization and the Drug Quality & Security Act

The supply chain for genuine pharmaceuticals has grown longer, and every…